Medtronic财报前瞻称新产品周期或支撑增长，但未披露新增经营事实

Oil jumps 3% as U.S. strikes on Iran revive Hormuz supply disruption concerns
Medtronic PLC is set to report first-quarter fiscal 2027 earnings before the market opens Tuesday, as investors assess whether a slate of new medical technologies can sustain the company’s strongest growth streak in a decade.
Analysts expect earnings of $1.39 per share, representing a 9.5% increase year-over-year, on revenue of $9.55 billion, up 11.3% from the prior-year period. Wall Street maintains a "Buy" consensus on the stock, with 29 analysts setting a mean price target of $98.84—implying roughly 8% upside from the current $91.23 share price.
EPS estimates have remained essentially flat over the past week and two months, while revenue estimates edged down slightly over the past 60 days, signaling stable but cautious expectations heading into the print.
The Dublin-based medical device giant, valued at $116.8 billion, has attracted bullish attention in recent weeks. TD Cowen raised its price target to $110 from $100, while Needham lifted its target to $114 from $101, both maintaining Buy ratings. The optimism centers on what Needham described as "the early stages of a strong product cycle."
What Investors Are Watching
First, product momentum across Medtronic’s key growth platforms will be scrutinized. The company’s cardiac ablation business has been a standout performer, with Medtronic recently winning expanded CE Mark approval for its Affera mapping and ablation system to treat ventricular arrhythmias. Analysts at TD Cowen noted the company has reported 80% growth in Cardiac Ablation Solutions, driven by the Affera technology and Sphere-9 catheter.
Second, reimbursement progress for the Symplicity renal denervation system remains critical. Piper Sandler analyst Matt O’Brien estimates approximately 55% of the target patient population currently has coverage—short of the 70% threshold historically associated with product adoption inflection points. Broader coverage from major insurers "could position Symplicity as more meaningful top-line contributor," the analyst noted.
Third, margin management amid tariff pressures will come into focus. TD Cowen projects roughly $75 million in tariff-related headwinds for the quarter, which management is expected to offset through selling, general and administrative expense efficiencies to keep operating margins stable year-over-year.
The quarter also benefits from an extra selling week, providing an estimated 500 to 600 basis points of revenue tailwind, according to analyst commentary.
In the prior quarter ended April 2026, Medtronic beat expectations on both top and bottom lines, posting $1.55 in adjusted earnings per share on revenue of $9.80 billion. That marked the company’s strongest annual revenue growth in a decade at 8.4%.
With shares trading at 15.3 times forward earnings and multiple analysts raising price targets ahead of the report, Tuesday’s results will test whether Medtronic’s portfolio of next-generation technologies—from robotic surgery to AI-powered platforms—can translate into sustained financial outperformance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.